AI Engines For more Details: Perplexity Kagi Labs You
Effectiveness: Penciclovir is effective in reducing the severity and duration of herpes outbreaks when applied topically to the affected area. It works by inhibiting the replication of the virus.
Side Effects: Common side effects of penciclovir cream include mild pain or stinging at the application site. Some people may experience itching, rash, or dry/cracked lips. These side effects are usually mild and transient.
Systemic Absorption: Penciclovir cream is generally well-tolerated because only a small amount of the drug is absorbed systemically through the skin. However, individuals should avoid applying it to mucous membranes or areas near the eyes to minimize absorption.
Allergic Reactions: While rare, some people may experience allergic reactions to penciclovir. Signs of an allergic reaction include rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, or trouble breathing. Seek immediate medical attention if you experience any of these symptoms.
Drug Interactions: Penciclovir cream is primarily applied topically, which reduces the likelihood of significant drug interactions compared to oral medications. However, it's always important to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.
Pregnancy and Breastfeeding: The safety of penciclovir during pregnancy and breastfeeding has not been established. Consult with a healthcare provider before using penciclovir if you are pregnant, planning to become pregnant, or breastfeeding.
Precautions: Penciclovir cream is for external use only. Avoid contact with the eyes, mouth, and other mucous membranes. Wash your hands before and after applying the medication. Do not cover the treated area with bandages or other dressings unless instructed by your healthcare provider.
Resistant Strains: Prolonged or frequent use of penciclovir cream may lead to the development of resistant strains of the virus. To minimize this risk, use penciclovir as directed by your healthcare provider and avoid using it more often or for longer than prescribed.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1.6 | 1.6 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1 | 0.8 | 0.25 |
| Allergies | 1.1 | 0.6 | 0.83 |
| Allergy to milk products | 0.6 | 0.7 | -0.17 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.9 | 1.9 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 1.2 | 0.6 | 1 |
| Anorexia Nervosa | 0.7 | 1.3 | -0.86 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.3 | 0.33 |
| Asthma | 1.7 | 1.1 | 0.55 |
| Atherosclerosis | 1 | 0.6 | 0.67 |
| Atrial fibrillation | 1.2 | 1 | 0.2 |
| Autism | 2.3 | 2.6 | -0.13 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 1 | 0.5 | 1 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.4 | -0.33 |
| Carcinoma | 2 | 1 | 1 |
| Celiac Disease | 0.8 | 1 | -0.25 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 0.9 | 1.5 | -0.67 |
| Chronic Kidney Disease | 1 | 1.1 | -0.1 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.1 | 0.09 |
| Chronic Urticaria (Hives) | 0.3 | 0.1 | 2 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 1.3 | 0.8 | 0.63 |
| Colorectal Cancer | 2.8 | 1.1 | 1.55 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.6 | 1 | -0.67 |
| COVID-19 | 1.6 | 1.6 | 0 |
| Crohn's Disease | 3.1 | 2 | 0.55 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.3 | 1.1 | -2.67 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 3.9 | 2.5 | 0.56 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 1 | 0.5 | 1 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.3 | 0.7 | 0.86 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 1 | 0.3 | 2.33 |
| Functional constipation / chronic idiopathic constipation | 1.2 | 1.4 | -0.17 |
| gallstone disease (gsd) | 0.6 | 0.8 | -0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.3 | 1 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.7 | |
| Graves' disease | 1 | 1.4 | -0.4 |
| Gulf War Syndrome | 0.3 | 0.1 | 2 |
| Halitosis | 1 | 0.3 | 2.33 |
| Hashimoto's thyroiditis | 1.3 | 0.6 | 1.17 |
| Heart Failure | 1.2 | 0.5 | 1.4 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.1 | 0.7 | -6 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 1.3 | 1.6 | -0.23 |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 1.3 | 0.5 | 1.6 |
| Inflammatory Bowel Disease | 2 | 2.8 | -0.4 |
| Insomnia | 0.7 | 1.1 | -0.57 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 1.7 | 1.8 | -0.06 |
| ischemic stroke | 1 | 0.8 | 0.25 |
| Liver Cirrhosis | 2.4 | 1.7 | 0.41 |
| Long COVID | 1.6 | 2.4 | -0.5 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.4 | 0.4 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.6 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.4 | 2.3 | 0.48 |
| Mood Disorders | 3.8 | 2.5 | 0.52 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 2.2 | 2 | 0.1 |
| Multiple system atrophy (MSA) | 0.5 | 0.5 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 0.8 | 1.13 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 2.7 | 2.9 | -0.07 |
| obsessive-compulsive disorder | 1.2 | 0.6 | 1 |
| Osteoarthritis | 0.6 | 0.6 | 0 |
| Osteoporosis | 0.8 | 0.6 | 0.33 |
| pancreatic cancer | 0.4 | 0.3 | 0.33 |
| Parkinson's Disease | 2.6 | 1.6 | 0.63 |
| Polycystic ovary syndrome | 2.3 | 1.4 | 0.64 |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.3 | 0.9 | -2 |
| Primary sclerosing cholangitis | 1.8 | 0.8 | 1.25 |
| Psoriasis | 0.7 | 1.6 | -1.29 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.6 | 0.56 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.9 | 1.3 | 0.46 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.7 | 0.7 | 0 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1.6 | 1.6 | 0 |
| Systemic Lupus Erythematosus | 1.7 | 0.5 | 2.4 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1 | 1.1 | -0.1 |
| Type 2 Diabetes | 2.8 | 2 | 0.4 |
| Ulcerative colitis | 1.4 | 1.7 | -0.21 |
| Unhealthy Ageing | 1.5 | 1 | 0.5 |
| Vitiligo | 1.2 | 0.4 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
